Gonadorelin
Gonadorelin is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 33515-09-2[1] |
| PubChem CID | 638793[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C55H75N17O13[1] |
| Molecular weight | 1182.3 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Gonadorelin is the decapeptide releasing hormone of the reproductive axis. Its retrieved literature is unusual in this dataset for being mostly veterinary: a 2009 Theriogenology paper compares gonadorelin products in lactating dairy cows, a 2015 Theriogenology paper reports effects of gonadorelin, lecirelin and buserelin on the luteinising hormone surge and ovulation, and a 1990 Theriogenology paper reports luteinising and follicle-stimulating hormone responses in Holstein heifers.
Human records in the retrieved set are diagnostic and pharmaceutical rather than therapeutic. A 2015 Obesity paper reports the impact of body mass index on a gonadorelin-stimulated luteinising hormone peak in premenarcheal girls, a 2017 JIMD Reports paper audits the use of gonadorelin analogues, and a 1988 Pharmaceutical Research paper reports an adjuvant effect of bacitracin on nasal absorption.
[3, 4, 5, 6, 7, 8]Reported mechanism
The releasing hormone of the reproductive axis; the retrieved records report luteinising hormone and follicle-stimulating hormone responses to its administration.
[5, 4]Stated in the titles of the cited 1990 and 2015 Theriogenology papers.
Targets named in the cited records: GnRH receptor, luteinising hormone release.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Gonadorelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- GnRH
- LHRH
- luteinising hormone-releasing hormone
Where this page sits
Research records
Cited research records for Gonadorelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Kisspeptin-10 — Endocrine and immune signalling peptides
- Thymosin alpha 1 — Endocrine and immune signalling peptides
- Leuprolide — Endocrine and immune signalling peptides
- Triptorelin — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Gonadorelin?
Gonadorelin is the decapeptide releasing hormone of the reproductive axis. Its retrieved literature is unusual in this dataset for being mostly veterinary: a 2009 Theriogenology paper compares gonadorelin products in lactating dairy cows, a 2015 Theriogenology paper reports effects of gonadorelin, lecirelin and buserelin on the luteinising hormone surge and ovulation, and a 1990 Theriogenology paper reports luteinising and follicle-stimulating hormone responses in Holstein heifers.
Which class is Gonadorelin indexed under?
Gonadorelin is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Gonadorelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 638793, Gonadorelin. PubChem, National Library of Medicine (2026). pubchem:638793
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:gonadorelin
- Comparison of gonadorelin products in lactating dairy cows: efficacy based on induction of ovulation of an accessory follicle and circulating luteinizing hormone profiles. Theriogenology (2009). pmid:19394072
- Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology (2015). pmid:25890780
- LH and FSH response of Holstein heifers to fertirelin acetate, gonadorelin and buserelin. Theriogenology (1990). pmid:16726818
- Impact of BMI on gonadorelin-stimulated LH peak in premenarcheal girls with idiopathic central precocious puberty. Obesity (Silver Spring, Md.) (2015). pmid:25645648
- An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom. JIMD reports (2017). pmid:28220410
- The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharmaceutical research (1988). pmid:3150047
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.